Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IN B001

X
Drug Profile

IN B001

Alternative Names: CJ-40010; EV71/CVA16 bivalent vaccine - HK inno.N; IN-B001

Latest Information Update: 28 Jan 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CJ HealthCare
  • Developer HK inno.N
  • Class Enterovirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Coxsackievirus infections

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for phase-I development in Coxsackievirus-infections(Prevention) in South Korea
  • 20 Nov 2020 HK inno.N Corporation plans a phase I trial for Coxsackievirus infections (Prevention) in South Korea in December 2020 (NCT04637919)
  • 18 Jun 2020 CJ HealthCare is now called HK inno.N

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top